RESMED INC

Listed Company

RSMDFCIK 0000943819OTCLarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Jun 30

Period

FY 2025

Revenue

$5.15B

Net Income

$1.40B

Total Assets

$8.17B

Equity

$5.97B

Shares Out

145.06M

Op. Cash Flow

$1.75B

RMD$198.99−22.37% · past yearDBEQ Basic

Daily closing prices

Business

ResMed Inc. is a global leader in digital health and cloud-connected medical devices for sleep apnea, COPD, and other chronic respiratory diseases. The company designs and manufactures CPAP, bilevel, ventilation, and diagnostic devices; mask systems and accessories; and cloud-based patient engagement and provider management platforms. ResMed operates two reportable segments: Sleep and Breathing Health, which comprises therapeutic devices, diagnostics, masks, and connected care solutions; and Residential Care Software, which provides cloud-based platforms for home medical equipment, home health, hospice, skilled nursing, and senior living providers. The company sells products in more than 140 countries through subsidiaries and independent distributors.

Summary from 10-K filed 2025-08-08

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net revenue	5,146	4,685	4,223	3,578	3,197
Cost of sales (exclusive of amortization shown separately below)	2,059	1,997	1,837	1,514	1,313
Amortization of acquired intangible assets	32	33	30	40	45
Total cost of sales	2,091	2,030	1,867	1,554	1,358
Gross profit	3,055	2,655	2,356	2,024	1,839
Selling, general, and administrative	991	917	874	738	670
Research and development	331	308	288	254	225
Amortization of acquired intangible assets	45	47	42	31	31
Restructuring expenses (note 17)	0	64	9	0	9
Acquisition related expenses	2	0	11	2	0
Total operating expenses	1,370	1,335	1,224	1,024	935
Income from operations	1,685	1,320	1,132	1,000	904
Interest income (expense), net	4	−46	−47	−22	—
Gain (loss) attributable to equity method investments (note 6)	4	−2	−7	−8	−11
Gain (loss) on equity investments (note 6)	−10	−4	10	−12	15
Gain on insurance recoveries	0	0	20	0	0
Other, net	−5	−3	−6	3	301,000
Total other income (loss), net	−8	−55	−30	−40	−20
Income before income taxes	1,678	1,265	1,102	960	884
Income taxes (note 12)	277	244	204	181	409
Net income	1,401	1,021	898	779	475
Basic earnings per share (note 11) (in dollars per share)	9.55	6.94	6.12	5.34	3.27
Diluted earnings per share (note 11) (in dollars per share)	9.51	6.92	6.09	5.3	3.24
Dividend declared per share (in dollars per share)	2.12	1.92	1.76	1.68	1.56
Basic shares outstanding (000's) (in shares)	147	147	147	146	145
Diluted shares outstanding (000's) (in shares)	147	148	147	147	146

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	1,209	238	228	274	295
Accounts receivable, net of allowances of $22,424 and $21,132 at June 30, 2025 and June 30, 2024, respectively	939	837	705	576	614
Inventories (note 4)	928	822	998	744	457
Prepaid expenses and other current assets (note 4)	429	460	437	338	208
Total current assets	3,506	2,358	2,368	1,931	1,575
Property, plant and equipment, net (note 4)	551	548	538	498	463
Operating lease right-of-use assets (note 9)	167	151	128	132	129
Goodwill (note 5)	3,047	2,842	2,770	1,936	1,928
Other intangible assets, net (note 5)	465	486	552	346	393
Deferred income taxes (note 12)	253	204	133	80	80
Prepaid taxes and other non-current assets	186	284	262	172	161
Total non-current assets	4,669	4,515	4,384	3,164	3,153
Total assets	8,174	6,872	6,752	5,096	4,728
Accounts payable	278	238	151	159	138
Accrued expenses (note 7)	402	378	366	345	321
Operating lease liabilities, current (note 9)	31	25	22	22	24
Deferred revenue	166	153	138	109	110
Income taxes payable (note 12)	132	108	72	45	308
Short-term debt, net (note 8)	10	10	10	10	12
Total current liabilities	1,019	911	759	689	912
Deferred revenue	157	137	119	95	91
Deferred income taxes (note 12)	78	79	91	10	11
Operating lease liabilities, non-current (note 9)	153	141	117	120	115
Other long-term liabilities	142	42	68	6	7
Long-term debt, net (note 8)	658	697	1,431	765	643
Long-term income taxes payable (note 12)	0	0	37	49	63
Total non-current liabilities	1,187	1,098	1,863	1,046	931
Total liabilities	2,207	2,008	2,622	1,735	1,842
Commitments and contingencies (note 15)	—	—	—	—	—
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	0	0	0	0	0
Common stock, $0.004 par value, 350,000,000 shares authorized; 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 and 189,565,112 issued and 146,901,045 outstanding at June 30, 2024	761,000	588,000	588,000	586,000	583,000
Additional paid-in capital	2,034	1,897	1,772	1,682	1,622
Retained earnings	6,081	4,992	4,253	3,614	3,080
Treasury stock, at cost, 43,925,747 shares at June 30, 2025 and 42,664,067 shares at June 30, 2024	−2,100	−1,773	−1,623	−1,623	−1,623
Accumulated other comprehensive loss	−75	−252	−273	−313	−193
Total stockholders equity	5,968	4,864	4,130	3,361	2,886
Total liabilities and stockholders equity	8,174	6,872	6,752	5,096	4,728

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Depreciation and amortization	198	177	165	160	157
Amortization of right-of-use assets	37	39	32	34	35
Stock-based compensation costs (note 10)	92	80	71	65	64
(Gain) loss attributable to equity method investments, net of dividends received (note 6)	−4	2	10	8	—
(Gain) loss on equity investments (note 6)	10	4	−10	12	—
Restructuring expenses (note 17)	0	33	9	0	—
Gain on insurance recoveries	0	0	−20	0	0
Accounts receivable	−77	−134	−107	19	−129
Inventories	−80	172	−249	−312	−22
Prepaid expenses, net deferred income taxes and other current assets	83	−115	−138	−168	−58
Accounts payable, accrued expenses and other	91	122	31	−248	211
Net cash provided by operating activities	1,752	1,401	693	351	737
Purchases of property, plant and equipment	−90	−99	−120	−135	−103
Patent registration costs	−11	−15	−14	−21	−14
Business acquisitions, net of cash acquired	−139	−133	−1,013	−43	−39
Purchases of investments (note 6)	−6	−13	−32	−21	−22
Proceeds from exits of investments (note 6)	5	1	4	7	0
Proceeds / (payments) on maturity of foreign currency contracts	42	−10	15	−17	19
Net cash used in investing activities	−200	−270	−1,160	−230	−158
Proceeds from issuance of common stock, net	74	53	49	47	38
Taxes paid related to net share settlement of equity awards	−18	−9	−31	−52	−50
Purchases of treasury stock	−300	−150	0	0	—
Payments of business combination contingent consideration	−855,000	−1	−2	0	−4
Acquisition of consolidated subsidiary	−11	0	0	—	—
Proceeds from borrowings, net of borrowing costs	0	105	1,070	288	90
Repayment of borrowings	−40	−835	−405	−166	−612
Dividends paid	−311	−282	−258	−245	−227
Net cash (used in) provided by financing activities	−606	−1,119	423	−128	−765
Effect of exchange rate changes on cash	26	−2	−2	−14	18
Net increase (decrease) in cash and cash equivalents	971	10	−46	−22	−168
Income taxes paid, net of refunds	214	278	217	478	221
Interest paid	28	46	47	22	24
Fair value of assets acquired, excluding cash	44	46	360	16	17
Liabilities assumed	−6	−8	−132	−5	−2
Goodwill on acquisition	101	92	787	39	25
Deferred payments	670,000	−143,000	3	−3	4
Fair value of contingent consideration	855,000	4	−2	0	0
Cash paid for acquisitions	140	135	1,015	43	44

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is RESMED INC's CIK number?

RESMED INC's SEC CIK number is 0000943819 (943819). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find RESMED INC's SEC filings?

All of RESMED INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did RESMED INC last report earnings?

RESMED INC (RSMDF) most recently filed an earnings 8-K with the SEC on Jul 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-297658). This is RESMED INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is RESMED INC's most recent earnings 8-K?

RESMED INC's latest earnings 8-K (Item 2.02) was filed Jul 7, 2026 under accession 0001193125-26-297658. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View RESMED INC's latest earnings 8-K →
Look up any company's CIK number →